This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Huntington’s disease (HD) is associated with a distinct profile of cognitive impairment that includes memory deficits (frontal type) and dysfunctions of various aspects of executive function, indicating a subcortical dementia.1 These behavioral changes can be observed early in the course of the disorder and psychiatric symptoms such as depression, personality changes, and psychotic symptoms are also associated with the syndrome. Suicidal behavior is commonly seen in patients with HD and is the cause of death in nearly 6% of patients.2
There is as yet no therapy that can effectively treat the neurologic pathology underlying HD; treatment is symptomatic. Riluzole, an antiglutamatergic drug, relieves symptoms of chorea and extends survival in patients with ALS and is currently being investigated for therapeutic efficacy in other neurodegenerative disorders, including HD.3,4⇓ Psychiatric symptoms are often treated with antipsychotics.
Case report.
A right-handed, 38-year-old woman was referred to the department of neurology in 1998 because of choreic hyperkinesias. Her medical history included depression since adolescence, which had been treated 2 years previously with psychotherapeutic counseling and since April 1999 with the antidepressant citalopram (10 mg/d).
Neurologic examinations and the initial neuropsychological evaluation of the patient revealed a mild cognitive impairment. A synopsis of the clinical results led to the preliminary diagnosis of HD. This diagnosis was confirmed by genetic analysis in May 1999. To relieve chorea, riluzole (50 mg/d twice daily) was prescribed in April 1999.
In June 1999, the patient attempted suicide by consuming 2,800 mg of …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Bradykinesia in early Huntington’s disease
Amnestic syndrome of the medial temporal type identifies prodromal AD
Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults
Effects of rivastigmine on cognitive function in patients with traumatic brain injury